Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Medtronic
Baxter
Fish and Richardson
UBS
Chinese Patent Office
Boehringer Ingelheim
Fuji
McKesson

Generated: February 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRAZODONE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Trazodone Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00000179 Agitation in Alzheimer's Disease Completed National Institute on Aging (NIA) Phase 3 Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective.
NCT00027053 Trazodone for Sleep Disturbance in Early Alcohol Recovery Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 This study is a randomized, double-blind clinical trial comparing trazodone (Desyrel) and placebo among sleep-disturbed, alcohol-dependent individuals shortly after discharge from an inpatient detoxification program. Subjects will undergo a baseline assessment and random assignment to trazodone or identical placebo for 12 weeks. All persons completing the alcohol detoxification at Stanley Street Treatment and Resources (SSTAR) will be screened. (SSTAR of Rhode Island provides detoxification services to non/underinsured persons of Rhode Island.)
NCT00027053 Trazodone for Sleep Disturbance in Early Alcohol Recovery Completed Rhode Island Hospital Phase 2 This study is a randomized, double-blind clinical trial comparing trazodone (Desyrel) and placebo among sleep-disturbed, alcohol-dependent individuals shortly after discharge from an inpatient detoxification program. Subjects will undergo a baseline assessment and random assignment to trazodone or identical placebo for 12 weeks. All persons completing the alcohol detoxification at Stanley Street Treatment and Resources (SSTAR) will be screened. (SSTAR of Rhode Island provides detoxification services to non/underinsured persons of Rhode Island.)
NCT00253890 Insomnia and Drug Relapse Risk Completed National Institute on Drug Abuse (NIDA) Phase 3 The purposes of this study are: 1. to evaluate the relationship between subjective complaints of sleep and objective measures of sleep quality, as measured through polysomnography, and 2. to evaluate the efficacy of trazodone, as compared to placebo, in individuals early in methadone maintenance.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Trazodone Hydrochloride

Condition Name

Condition Name for Trazodone Hydrochloride
Intervention Trials
Healthy 5
Depression 5
Insomnia 5
Major Depressive Disorder 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Trazodone Hydrochloride
Intervention Trials
Disease 7
Sleep Initiation and Maintenance Disorders 6
Depressive Disorder 5
Depression 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Trazodone Hydrochloride

Trials by Country

Trials by Country for Trazodone Hydrochloride
Location Trials
United States 67
Canada 7
China 3
Switzerland 2
Spain 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Trazodone Hydrochloride
Location Trials
New York 7
California 6
Ohio 4
Georgia 4
Pennsylvania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Trazodone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Trazodone Hydrochloride
Clinical Trial Phase Trials
Phase 4 11
Phase 3 9
Phase 2/Phase 3 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Trazodone Hydrochloride
Clinical Trial Phase Trials
Completed 20
Recruiting 9
Not yet recruiting 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Trazodone Hydrochloride

Sponsor Name

Sponsor Name for Trazodone Hydrochloride
Sponsor Trials
Labopharm Inc. 5
Aziende Chimiche Riunite Angelini Francesco S.p.A 4
Lee's Pharmaceutical Limited 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Trazodone Hydrochloride
Sponsor Trials
Other 29
Industry 19
NIH 9
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Express Scripts
Covington
Teva
McKesson
Baxter
Cantor Fitzgerald
Johnson and Johnson
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.